NIDA is offering the Translational Avant-Garde Award to fund researchers in developing medications for Substance Use Disorders. The award aims to support innovative basic and clinical researchers to translate discoveries into SUD medication for various substances. The grant includes UH2 and UH3 phases, with funding for milestone completion and drug development. Successful projects from UH2 will transition to UH3 phase. Applicants should demonstrate the ability to progress molecules towards FDA approval, attracting talented investigators to expand the pipeline for addiction treatment and clinical testing. Closing date: Apr 15, 2015.
Opportunity ID: 271611
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DA-15-017 |
| Funding Opportunity Title: | NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UH2/UH3) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | 3 |
| Assistance Listings: | 93.279 — Drug Abuse and Addiction Research Programs |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jan 16, 2015 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Apr 15, 2015 |
| Current Closing Date for Applications: | Apr 15, 2015 |
| Archive Date: | May 16, 2015 |
| Estimated Total Program Funding: | $3,000,000 |
| Award Ceiling: | $1,000,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments Small businesses Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) Special district governments Independent school districts Public and State controlled institutions of higher education County governments Public housing authorities/Indian housing authorities For profit organizations other than small businesses Private institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this award is to support outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications for the treatment of Substance Use Disorders (SUDs) stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use.Eligible applicants must demonstrate the ability to develop molecules with the potential to treat SUDs and advance them in the drug development continuum. The ultimate goal of this FOA is to bring molecules closer to FDA approval.
The UH2/UH3 Phase Innovation Awards Cooperative Agreement involves 2 phases.The UH2 is to support a project with specific milestones to be accomplished at the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UH2.UH2 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UH2 and UH3 phases. Through this FOA, NIDA seeks to attract exceptionally talented investigators to the mission of expanding the number and breadth of lead molecules in the pipeline for drug addiction treatment, optimizing these leads, and/or advancing them to clinical testing. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-15-017.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-C | FORMS-C | PKG00211886 | Mar 15, 2015 | Apr 15, 2015 | View |
Package 1
Mandatory forms
271611 RR_SF424_2_0-2.0.pdf
271611 PHS398_ResearchPlan_2_0-2.0.pdf
271611 PHS398_CoverPageSupplement_2_0-2.0.pdf
271611 RR_Budget_1_3-1.3.pdf
271611 RR_KeyPersonExpanded_2_0-2.0.pdf
271611 RR_OtherProjectInfo_1_3-1.3.pdf
271611 PerformanceSite_2_0-2.0.pdf
Optional forms
271611 PlannedReport-1.0.pdf
271611 PHS398_CumulativeInclusionReport-1.0.pdf
271611 RR_SubawardBudget30_1_3-1.3.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
